MAPS Bulletin Summer 1989 Vol. 1, No. 2
Before studies evaluating possible benefits from MDMA, the FDA requires that MDMA’s risks be carefully evaluated. Dr. Ricaurte’s study of MDMA users will lead to the FDA’s ability to make more informed assessments concerning the risks of MDMA, replacing fear with facts. Subjects will have all expenses covered to Baltimore, and be given a fee of $400. If you or anyone you know is interested in volunteering, you can write or call me for more details. Though not the ideal vacation, it is fascinating to learn how one measures on all these various tests. It is also a very valuable towards helping clarify our national policy towards MDMA. Due to confidentiality, identities of participants will not be disclosed. Even the Director of NIDA has no inherent right to see medical files.